We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Microsensor Measures Intraocular Pressure in Glaucoma

By HospiMedica International staff writers
Posted on 18 Aug 2014
Print article
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
Image: The Pro-IOP eye pressure measurement system implant (Photo courtesy of Implandata Ophthalmic Products).
An implantable microsensor for wireless intraocular pressure (IOP) measurement allows close monitoring of patients’ disease status and glaucoma therapy success.

The Pro-IOP eye pressure measurement system consists of an implantable microsensor, an external hand held device that telemetrically transfers energy to the microsensor, and a cellular GSM module, which connects with the hand held device to transfer measurement data to a database that can be accessed by clinicians to review the disease status of the patient. Optionally, the patient can also have limited access to the data via an App, in order to review data history or communicate with the ophthalmologist.

The Pro-IOP delivers direct and real IOP, as expressed in mm Hg, which facilitates measurement without disrupting the patient’s lifestyle and without compromising the patient’s behavior. At the same time, the system discloses to clinicians real time, crucial information regarding patient specific pressure fluctuation and variability, shows if the chosen therapeutic measures work, and reports patient therapy adherence. The system is designed for easy patient use and can also be integrated into telemedicine systems for remote patient management.

The Pro-IOP eye pressure measurement system is a product of Implandata Ophthalmic Products (Hannover, Germany). The company has recently reported the successful implantation of the first patient within the ARGOS-02 clinical study, held at Augenklinik Bellevue (Kiel, Germany). In the ARGOS-02 clinical study, six eye centers in Germany are currently recruiting primary open angle glaucoma patients undergoing cataract extraction.

“So far the first results of this innovative product are very compelling,” said Prof. Detlef Uthoff, MD, medical director of Augenklinik Bellevue. “Up to date, early diagnosis and therapeutic management of the disease have been rather dissatisfying for eye doctors. But this innovation allows us for the first time to personalize and control therapy according to the specific needs of the glaucoma patient.”

Related Links:

Implandata Ophthalmic Products
Augenklinik Bellevue


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Pressure Monitoring Mattress
Entrix NX
New
Transfer Trolley
E-Med 1500 Trolley

Print article

Channels

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.